GNTA - Genenta Science SpA Debt to Book Capitalization Ratio

Genenta Science S.p.A. (GNTA) brings together leading geneticists to create innovative lentiviral brain therapies. Developing methods to combat solid tumors through targeted drug delivery reduces risks. The GURU.Markets service features a line chart of the debt-to-equity ratio, where 0.33 serves as the final level marker. The lack of profit during the testing stage makes the financial position dependent on external partners.

GNTA Genenta Science SpA: Debt to Book Capitalization Ratio in the range 07/04/2022 - 10/28/2026

Summary analytical data breakdowns for genenta.com (GNTA)

- price and consensus price forecast:

Stock Price Genenta Science|GNTA - Consensus Target

- market capitalization data:

Market Value Genenta Science S.p.A.|GNTA - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Genenta Science|GNTA - Company Book Value|Market Value to Book Value Ratio genenta.com|GNTA - Company Assets

- debt and liquidity data:

Total Debt to Capital Genenta Science S.p.A.|GNTA - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Genenta Science|GNTA - Company Cumulative Debt|Debt to Book Value Genenta Science S.p.A.

Analysis of all company metrics:GNTA, Genenta

Finished products of Genenta Science SpA

The diversification of the Genenta Science (GNTA) gene-therapy platform across various tumor types minimizes the risks of clinical failures. An analysis of the debt-to-book capitalization ratio allows for an assessment of this strategy's resilience. This metric compares total loans against net assets, identifying financing overheating or inefficient capital utilization. A lower ratio protects the investor from debt traps. This balance sheet confirms the asset's financial viability.

Competitors of Genenta Science S.p.A.